January 15, 2021 8:07am
Always maintain a perspective and know “how to get out of Dodge” – (a metaphor)!
Pre-open indication: 9 SELLs and 0 BUY
What I provide is a trusted source of share pricing intelligence that ensures that investors are kept apprised of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!
Dow futures are down -0.42% (-131 points), S&P futures are down -0.34% (-13 points) and NASDAQ futures are DOWN -0.08% (-10 points)
Stock futures fell on Friday as details of a $1.9 trillion fiscal aid/stimulus plan became public sponsoring future debt while bank earnings reporting season ramps;
European markets traded in negative territory with political turmoil in Italy and Germany followed with the U.K. economy declining -2.6% in November as the country implemented fresh lockdown measures;
Asia-Pacific markets started up, but tailed off by the afternoon as rising Covid-19 cases in China have led to lockdowns in several cities, resurfacing concerns.
Henry’omics:
Although markets were expecting a huge fiscal aid package, the state and local government bail-outs add include another $350 billion whose budgeting management has long been in question.
The big three gene-editing stocks <CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and Intellia Therapeutics (NTLA)> have more than doubled in the past few months. My question is how long before the “profit harvesters” initiate decline as trading volume has expanded this month while prices have increased?
Data Docket: data on retail sales and inflation
Thursday’s evening’s recap: RegMed Investors’ (RMi) closing bell: “Trading volume has expanded this month as prices have increased” … https://www.regmedinvestors.com/articles/11722
- The Nasdaq closed DOWN -16.31 points (-0.12%);
- The IBB closed up +2.43% and XBI closed up +3.27%;
- Sector volume was LOW with 10 of the 27-upside having higher than the 3-month average volume with the increased volume of 1 of 7-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was up +1.04 points or +4.68% at 23.25;
- Thursday’s percentage (%) of the 27-upside were +0.13% (QURE) to +9.59% (NTLA) while the 7-downside ranges from -1.69% (BSTG) to -5% (RENE.L);
January:
- 7 positive and 2 negative closes, so far
Companies in my headlights – It’s your decision; I provide an idea and context:
Maintaining Sell:
Biostage (BSTG) closed down -$0.02 to $1.16 with 295 shares traded after Wednesday’s -$0.00 to $1.18 with 411 shares traded after Tuesday’s $1.18 with 3,500 shares traded and Monday’s $1.16 with 3,202 shares traded. Reiterating the WHY questions …
- Question#1: WHY does as the share price need to be "propped or pumped" and WHICH “investors” are “stimulating” the volume?
- Question#2: Does it have anything to do with a 52-week low of $0.80 as well as a high of $4.88, a current share price of $1.16 following the last price placement priced at $4.00?
- Question#3: WHY the extension, “BSTG issued warrants to acquire shares of common stock with an exercise price of $3.70 per share that were exercisable until December 31, 2020. On 12/30/20, BSTG agreed to ... extend the expiration date .... to June 30, 2021 with respect to warrants exercisable for an aggregate of 122,554 shares of common stock - their only form of raising capital.
- Question#4: Don’t U.S. public shareholders deserve accountability!
- Question#5: A precarious capital formation platform - they’re running-out of warrant conversions?
- Question#6: Reiterating, WHAT is “with” the $75 million raised and all but spent on getting to an IND with … NO clinical trial initiation?
SELL:
Athersys (ATHX) closed up +$0.07 to $2.01, after Wednesday’s $1.94, Tuesday’s $2.00 and Monday’s1.92 and last Friday’s $1.96 and has a negative -$0.02 or -1% aftermarket indication;
SELL into Strength:
BioLife Solutions (BLFS) closed down -$0.54 to $41.93 after Wednesday’s $42.47, Tuesday’s $40.11, Monday’s $40.45 and last Friday’s $40.80 with a positive +$0.24 or +0.57% aftermarket indication;
Global Blood Therapeutics (GBT) closed up +$0.73 to $49.77, after Wednesday’s $49.04, Tuesday’s $46.14 and Monday’s $45.90 and last Friday’s $48.81 and has a positive +$0.63 or +1.27% aftermarket indication;
Precigen (PGEN) closed up +$0.19 to $8.61 after Wednesday’s -$0.25 to $8.42, Tuesday’s $8.67 and Monday’s $8.85 and has a positive +$0.06 or -0.70% aftermarket indication;
Sage Therapeutics (SAGE) closed up +$0.53 to $96.76 after Wednesday’s $, Tuesday’s $, Monday’s $ and last Friday’s $ with a negative -$0.56 or -0.58% aftermarket indication;
SELL from BUY:
bluebird bio (BLUE) closed up +2.36 to $51.85 after Wednesday’s -$2.84 to $49.49, Tuesday’s +$1.93 to $52.33 after Monday’s $50.40 and Friday’s $48.54 with a negative -$0.85 or -1.64% aftermarket indication;
Ultragenyx (RARE) closed up +$5.16 to $139.87 after Wednesday’s -$2.93 to $134.71, Tuesday’s $137.64 and Monday’s $141.74 with a negative -$1.58 or -1.13% aftermarket indication;
Verastem (VSTM) closed up +$0.05 to $2.42 after Wednesday’s -$0.08 to $2.37, Tuesday’s $2.45, Monday’s $2.35 and last Friday’s $2.53 with a negative -$0.02 or -0.83% aftermarket indication;
The BOTTOM LINE: "Everything we hear is an opinion, not a fact. Everything we see is a perspective, not the truth." ... Marcus Aurelius
Investors also need to portfolio distance from those companies with capital structure irregularities and diminished cash positions.
Welcome to my world of defining the “grey’ in our universe! I can’t get-off this thematic: are “looking for reasons to BUY stocks.”
Earnings season Is about to begin. Investors are considering whether they should ignore and wait for Q2.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
